Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market - 2025-2033

April 2026 | 94 pages | ID: GB93C7AE8C4AEN
DataM Intelligence

Abstracts

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market reached US$ 8.56 Billion in 2025 and is expected to reach US$ 31.76 Billion by 2033, growing with a CAGR of 17.70% during the forecast period 2026-2033.

The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Drug Class

• Thyroid Hormone Receptor-? (THR-?) Agonists*
• Resmetirom
• VK2809
• Peroxisome Proliferator-Activated Receptor (PPAR) Agonists
• Lanifibranor
• GLP-1 Receptor Agonists
• Semaglutide
• GLP-1 / Glucagon Dual Receptor Agonists
• Survodutide
• Fibroblast Growth Factor 21 (FGF21) Analogues
• Pegozafermin
• Efruxifermin
• Acetyl-CoA Carboxylase (ACC) Inhibitors
• Denifanstat
• Others

By Fibrosis Stage

• F0–F1*
• F2–F3
• F4

By Age Group

• Adults*
• Geriatrics
• Pediatrics

By Distribution Channel

• Hospital Pharmacies*
• Retail Pharmacies
• Online Pharmacies

By End User

• Hospitals*
• Specialty Clinics
• Ambulatory Surgical Centers

Regional Analysis for Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. DEFINITION AND OVERVIEW

1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period

2. EXECUTIVE SUMMARY

2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Rising Global Burden of Obesity and Metabolic Syndrome
    3.1.1.2. Advancements in Drug Development and Clinical Research
    3.1.1.3. Increasing Awareness and Diagnosis of Liver Diseases
  3.1.2. Restraints
    3.1.2.1. Lack of Widely Approved and Effective Therapies
    3.1.2.2. High Treatment Costs and Limited Reimbursement
    3.1.2.3. Stringent Regulatory Requirements for Drug Approval
  3.1.3. Opportunity
    3.1.3.1. Growing Demand for Effective Therapies for Untreated MASH Population
    3.1.3.2. Increasing Adoption of Precision Medicine and Targeted Therapies
  3.1.4. Trends
    3.1.4.1. Expansion of GLP-1-Based Therapeutic Approaches
    3.1.4.2. Rising Clinical Trials and Strong Drug Development Pipeline
  3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

4.1. Porter's Five Force Analysis – Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market
4.2. Geopolitical & Supply Chain Exposure
  4.2.1. API sourcing concentration for MASH drug development and manufacturing
  4.2.2. Trade policies, export controls, and pharmaceutical supply chain risks
4.3. Social & Patient-Centric Factors
  4.3.1. Physician prescribing behavior in metabolic and liver disease treatment
  4.3.2. Patient adherence challenges in long-term metabolic and liver disease therapies
  4.3.3. Treatment switching patterns between metabolic and liver disease therapies
  4.3.4. Awareness gaps and underdiagnosis of MASH among at-risk populations
4.4. Economic Factors
  4.4.1. Healthcare expenditure and reimbursement policies for MASH therapies
  4.4.2. Rising R&D costs and manufacturing expenses for innovative liver disease drugs
  4.4.3. Economic burden of metabolic disorders and impact on treatment demand
4.5. Pricing Analysis
  4.5.1. Pricing dynamics of innovative MASH therapies and emerging treatment options
4.6. Regulatory Analysis
  4.6.1. Regulatory approval pathways for MASH drug candidates
  4.6.2. Post-marketing surveillance and pharmacovigilance requirements
  4.6.3. GMP compliance and regulatory inspection risks in pharmaceutical manufacturing
  4.6.4. Regulatory alignment across major agencies, including FDA, EMA, PMDA, NMPA, and CDSCO
4.7. Go-To-Market (GTM) Strategy
  4.7.1. Hospital, specialty clinic, and hepatology network penetration strategies
4.8. Innovation & R&D Trends
  4.8.1. Development of next-generation metabolic and anti-fibrotic therapies
  4.8.2. Combination therapy strategies targeting metabolic dysfunction and liver fibrosis
4.9. Sustainability and ESG Analysis
  4.9.1. Responsible sourcing of pharmaceutical ingredients and sustainable manufacturing practices
4.10. Ecosystem Participants
  4.10.1. Branded MASH drug developers and pharmaceutical companies
  4.10.2. Biotechnology firms developing novel metabolic and liver disease therapies
  4.10.3. API and pharmaceutical ingredient suppliers
  4.10.4. Contract research, manufacturing, and packaging organizations
  4.10.5. Healthcare providers, distributors, and specialty pharmacy networks
4.11. Buyer Decision Criteria & Adoption Drivers
  4.11.1. Clinical efficacy and safety profile of emerging MASH therapies
  4.11.2. Regulatory approval status and clinical evidence
  4.11.3. Pricing, reimbursement, and patient access programs
  4.11.4. Treatment outcomes and long-term disease management benefits
4.12. DMI Opinion – Strategic Outlook for the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market

5. BY DRUG CLASS

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  5.1.2. Market Attractiveness Index, By Drug Class
5.2. Thyroid Hormone Receptor-? (THR-?) Agonists*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  5.2.3. Resmetirom
  5.2.4. VK2809
5.3. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists
  5.3.1. Lanifibranor
5.4. GLP-1 Receptor Agonists
  5.4.1. Semaglutide
5.5. GLP-1 / Glucagon Dual Receptor Agonists
  5.5.1. Survodutide
5.6. Fibroblast Growth Factor 21 (FGF21) Analogues
  5.6.1. Pegozafermin
  5.6.2. Efruxifermin
5.7. Acetyl-CoA Carboxylase (ACC) Inhibitors
  5.7.1. Denifanstat
5.8. Others

6. BY FIBROSIS STAGE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
  6.1.2. Market Attractiveness Index, By Fibrosis Stage
6.2. F0–F1*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. F2–F3
6.4. F4

7. BY AGE GROUP

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  7.1.2. Market Attractiveness Index, By Age Group
7.2. Adults*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Geriatrics
7.4. Pediatrics

8. BY DISTRIBUTION CHANNEL

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies

9. BY END USER

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Ambulatory Surgical Centers

10. BY REGION

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  10.1.2. Market Attractiveness Index, By Region
10.2. North America
  10.2.1. Introduction
  10.2.2. Key Region-Specific Dynamics
  10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
  10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.2.8.1. US
    10.2.8.2. Canada
    10.2.8.3. Mexico
10.3. Europe
  10.3.1. Introduction
  10.3.2. Key Region-Specific Dynamics
  10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
  10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.3.8.1. Germany
    10.3.8.2. United Kingdom
    10.3.8.3. France
    10.3.8.4. Italy
    10.3.8.5. Spain
    10.3.8.6. Netherlands
    10.3.8.7. Switzerland
    10.3.8.8. Sweden
    10.3.8.9. Norway
    10.3.8.10. Denmark
    10.3.8.11. Belgium
    10.3.8.12. Poland
    10.3.8.13. Austria
    10.3.8.14. Ireland
    10.3.8.15. Portugal
    10.3.8.16. Greece
    10.3.8.17. Finland
    10.3.8.18. Rest of Europe
10.4. Latin America
  10.4.1. Introduction
  10.4.2. Key Region-Specific Dynamics
  10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
  10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.4.8.1. Brazil
    10.4.8.2. Argentina
    10.4.8.3. Mexico
    10.4.8.4. Chile
    10.4.8.5. Colombia
    10.4.8.6. Peru
    10.4.8.7. Rest of Latin America
10.5. Asia-Pacific
  10.5.1. Introduction
  10.5.2. Key Region-Specific Dynamics
  10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
  10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.5.8.1. China
    10.5.8.2. Japan
    10.5.8.3. India
    10.5.8.4. South Korea
    10.5.8.5. Australia
    10.5.8.6. New Zealand
    10.5.8.7. Singapore
    10.5.8.8. Malaysia
    10.5.8.9. Thailand
    10.5.8.10. Indonesia
    10.5.8.11. Vietnam
    10.5.8.12. Philippines
    10.5.8.13. Taiwan
    10.5.8.14. Rest of Asia Pacific
10.6. Middle East and Africa
  10.6.1. Introduction
  10.6.2. Key Region-Specific Dynamics
  10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Fibrosis Stage
  10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.6.8.1. Saudi Arabia
    10.6.8.2. United Arab Emirates
    10.6.8.3. Qatar
    10.6.8.4. Kuwait
    10.6.8.5. Oman
    10.6.8.6. Bahrain
    10.6.8.7. South Africa
    10.6.8.8. Egypt
    10.6.8.9. Nigeria
    10.6.8.10. Morocco
    10.6.8.11. Rest of Middle East & Africa

11. COMPETITIVE LANDSCAPE ANALYSIS

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
11.4. Partner Identification Analysis
11.5. Investment & Funding Landscape
11.6. Strategic Alliances & Innovation Pipelines

12. COMPANY PROFILES

12.1. Madrigal Pharmaceuticals, Inc.*
  12.1.1. Company Overview
  12.1.2. Product Portfolio
  12.1.3. Revenue Analysis
  12.1.4. Pricing Analysis
  12.1.5. SWOT Analysis
  12.1.6. Recent Developments
    12.1.6.1. Major Deals
    12.1.6.2. M&A
    12.1.6.3. Collaboration
    12.1.6.4. Acquisition
    12.1.6.5. Joint Ventures
    12.1.6.6. Innovations
  12.1.7. Recent News
    12.1.7.1. Events
    12.1.7.2. Conferences
    12.1.7.3. Symposiums
    12.1.7.4. Webinars
12.2. Novo Nordisk A/S
12.3. Boehringer Ingelheim International GmbH
12.4. Akero Therapeutics, Inc.
12.5. 89bio, Inc.
12.6. Inventiva
12.7. Sagimet Biosciences Inc.
12.8. Viking Therapeutics
12.9. CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
12.10. Gilead Sciences, Inc. . (LIST NOT EXHAUSTIVE)

13. GLOBAL METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) DRUGS MARKET – RESEARCH METHODOLOGY

13.1. Research Data
  13.1.1. Secondary Data
  13.1.2. Primary Data
  13.1.3. CAGR Analysis
13.2. Market Size Estimation Methodology
  13.2.1. Bottom-Up Approach
  13.2.2. Top-Down Approach
13.3. Market Breakdown & Data Triangulation
13.4. Research Assumptions
13.5. Limitations

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us